Niche Focus Surface Ophthalmics specializes in ophthalmology therapeutics with a proprietary delivery system, creating distinct opportunities to introduce advanced ocular treatments to eye care providers and clinics focused on dry eye syndrome and other ocular diseases.

Innovative Pipeline With three proprietary drug candidates leveraging the patented Klarity® delivery system, the company presents multiple avenues for partnership or distribution within the ophthalmic pharmaceutical market, appealing to researchers and healthcare providers seeking novel treatments.

Leadership Expansion Recent appointment of Richard Lindstrom as Founder & Chairman signals a strategic shift and renewed focus on addressing unmet needs in dry eye treatment, opening channels for collaborations and endorsement opportunities with key opinion leaders.

Funding & Growth Although currently small with revenue between one to ten million dollars, the company’s recent funding of 5.8 million dollars provides additional capital to scale clinical trials, manufacturing, and sales efforts targeting ophthalmology clinics and optometrists.

Market Differentiation By emphasizing efficiency, clinical advantages, and deep expertise, Surface Ophthalmics can competitively position itself against larger players like Allergan and Novartis, offering personalized and innovative therapeutic options to eye care professionals.